FNArena Windows

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

ResMed will acquire Propeller Health, which provides connected care for patients with COPD and asthma. Brokers believe the acquisition puts ResMed at the forefront of this market.

Dec 06 2018

Brokers consider Fisher & Paykel Healthcare is overvalued, as litigation and competitive headwinds buffet the business.

Nov 27 2018


ASX CODE LAST PRICE % MOVE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET UPSIDE/DOWNSIDE
CAT $0.95

-1.04%

$2.06 $0.95

$1.88

97.9%

COH $171.89

0.85%

$221.44 $155.22 36.0

$178.855

4.1%

FPH $11.68

-1.43%

$15.07 $11.18 34.6

IDX $2.66

2.31%

$3.22 $1.99 15.0

$3.113

17.0%

IPD $0.25

8.70%

$1.07 $0.21

$1.28

412.0%

MX1 $0.37

5.71%

$0.47 $0.27

$0.58

56.8%

NAN $3.04

2.70%

$3.86 $2.26 100.0

$3.32

9.2%

ONE $0.60 0.00% $2.81 $0.60

$3.20

433.3%

RAP $0.12

9.09%

$0.28 $0.07

$0.24

100.0%

RMD $15.94

0.89%

$16.04 $10.78 32.1

$15.605

-2.1%

RVA $0.20 0.00% $0.68 $0.18

$0.66

230.0%

SOM $1.92 0.00% $3.93 $1.46

$2.15

12.0%

VHT $1.15

7.48%

$1.55 $0.57

$1.535

33.5%

Previous Stories
ResMed Expands Presence In Home Health

Nov 07 2018

The price ResMed is paying for MatrixCare is rich, although brokers accept the deal will significantly expand its offering in home health data analytics.


ResMed Increases Market Dominance

Oct 29 2018

ResMed has impressed with solid revenue growth across all divisions in the September quarter, while an expanding digital platform is driving re-supply and improving adherence to the company’s products.


Nanosonics: Buy The Dips

Oct 02 2018

Michael Gable of Fairmont Equities suggests Nanosonics has broken outof its period of pullback.


Consumables Income Flows For Nanosonics

Aug 22 2018

While the US market dominates earnings for infection control developer Nanosonics, other markets are growing rapidly.


Expanded Product Offering Underpins ResMed

Aug 06 2018

Robust US economic conditions in FY19 should support ResMed amid stable pricing and an expanding product pipeline.


Brokers Diverge On ResMed Outlook

Apr 30 2018

While all acknowledge robust earnings growth in the March quarter, brokers diverge on whether the outlook for ResMed justifies an outperform rating.


G Medical Launches Mobile Health Monitoring

Apr 10 2018

G Medical Innovations is a small medical device company with two key products it intends to distribute globally. TMT Analytics initiates coverage.


Medical Developments Pain Free In Germany

Apr 09 2018

Brokers welcome the news that Medical Developments has received regulatory approval to market its pain-killing device Penthrox in Germany.


Buying Opportunity In Nanosonics?

Feb 27 2018

Has a buying opportunity presented in Nanosonics after the first half fell short of expectations?


Uncertainty Stymies Integral Diagnostics

Jan 30 2018

Integral Diagnostics performed strongly in the first half and FY18 guidance was recently upgraded but not all brokers are happy with the outlook.